.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Argus Health
Moodys
Daiichi Sankyo
Accenture
Novartis
Mallinckrodt
UBS
McKinsey
Cantor Fitzgerald

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Benoit (Bordeaux, FR)
Assignee: Universite de Bordeaux (Bordeaux, FR) Centre Hospitalier Universitaire de Bordeaux (Talence, FR)
Filing Date:Nov 16, 2012
Application Number:13/678,902
Claims:1. A method for treating an infant or small child for an infantile hemangioma, the method comprising administering to the infant or small child a medicament comprising a pharmaceutically acceptable and efficient dose of timolol.

2. The method of claim 1, wherein the medicament is for oral or topical administration.

3. A method for treating a hemangioma comprising administering to a patient in need thereof a pharmaceutically acceptable and efficient dose of timolol, wherein the hemangioma is a capillary hemangioma or capillary infantile hemangioma, and the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient.

4. The method of claim 1, wherein the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient.

5. The method of claim 4, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient.

6. The method of claim 3, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and an orodispersible dosage forms.

7. The method of claim 3, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams.

8. The method of claim 3, wherein the timolol is administered in a medicament for nasal, buccal, sublingual, or rectal administration.

9. The method of claim 4, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient.

10. The method of claim 1, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms.

11. The method of claim 1, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams.

12. The method of claim 1, wherein the timolol is administered in a medicament for nasal, buccal, sublingual, or rectal administration.

13. The method of claim 2, wherein the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient.

14. The method of claim 13, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient.

15. The method of claim 2, wherein the timolol is administered orally in a medicament selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms.

16. The method of claim 2, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Covington
Moodys
Mallinckrodt
Deloitte
US Department of Justice
Novartis
Argus Health
Colorcon
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot